Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:atccode |
L01 XE34
|
| gptkbp:brand |
Alunbrig
|
| gptkbp:casnumber |
1195760-78-6
|
| gptkbp:chemical_formula |
C22 H24 Cl N5 O2 S
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:ARIAD_Pharmaceuticals
|
| gptkbp:dosage_form |
250 mg tablet
|
| gptkbp:effective_date |
gptkb:2017
|
| https://www.w3.org/2000/01/rdf-schema#label |
brigatinib
|
| gptkbp:mechanism_of_action |
ALK inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea elevated liver enzymes |
| gptkbp:targets |
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:ALK_gene_rearrangements
gptkb:JAK1 gptkb:anaplastic_lymphoma_kinase_protein |
| gptkbp:bfsLayer |
7
|